# China NMPA Drug Inspection - Leshan Geriatric Specialist Hospital - Hawthorn Capsules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/leshan-geriatric-specialist-hospital/b1ee8640-86bb-48cb-b12c-c425ec61bf62/
Source feed: China

> China NMPA drug inspection for Leshan Geriatric Specialist Hospital published October 08, 2021. Drug: Hawthorn Capsules. On October 8, 2021, the Sichuan Provincial Drug Administration issued an announcement regarding quality failures in thre

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Sichuan Provincial Drug Administration Regarding 3 Batches of Drugs That Failed to Meet Regulations
- Company Name: Leshan Geriatric Specialist Hospital
- Publication Date: 2021-10-08
- Drug Name: Hawthorn Capsules
- Inspection Finding: Moisture content and fill weight discrepancies do not meet regulations
- Action Taken: Relevant enterprises and units are required to take risk control measures such as suspending sales and use and recalling products, investigate the reasons for non-compliance and make effective rectifications; the drug regulatory authorities shall initiate an investigation.
- Summary: On October 8, 2021, the Sichuan Provincial Drug Administration issued an announcement regarding quality failures in three batches of pharmaceutical products. The inspection identified non-compliant drugs from three entities: Sichuan Tongshantang Traditional Chinese Medicine Pieces Co., Ltd., Chongqing Kerui Pharmaceutical (Group) Co., Ltd., and Leshan Geriatric Hospital. Testing conducted by various municipal food and drug inspection centers revealed that the products failed to meet specific safety and quality standards. Key violations included improper physical appearance and medicinal impurities in Sichuan Tongshantang’s herbal products, weight variation in Chongqing Kerui’s tablets, and excessive moisture content and fill weight inconsistency in capsules produced by Leshan Geriatric Hospital.

Under the framework of the 'Drug Administration Law of the People's Republic of China,' the provincial authorities have mandated immediate corrective actions. The involved organizations must suspend all sales and use of the affected batches and initiate formal drug recalls. Additionally, they are required to conduct root-cause investigations and implement effective rectifications to prevent future non-compliance. The Sichuan Provincial Drug Administration has also instructed local departments to pursue legal investigations into the production and sale of these substandard medicines, with a commitment to publicly disclosing the final results of these inquiries.

Company: https://www.globalkeysolutions.net/companies/leshan-geriatric-specialist-hospital/1065cd65-4619-4a72-b94d-f04616ace2f8/